- Pneumococcal disease is a bacterial infection occurring worldwide acquired through direct contact with respiratory secretions from infected persons.
- Risk is increased for infants, young children, the elderly, and persons with underlying medical conditions. In temperate climates, pneumococcal disease is more common in winter and early spring.
- Symptoms include sudden onset of fever, chills, cough, difficulty or rapid breathing, and chest pain.
- Consequences of infection include inflammation of brain membranes, respiratory failure, or blood infection.
- Prevention includes observing respiratory hygiene (cough and sneeze etiquette) and hand hygiene (frequent, thorough handwashing).
- Two types of pneumococcal vaccine are available, and many people will need both. Prevnar 13 is routinely given to infants in a 4-dose series, whereas Pneumovax 23 is given routinely as a single-dose to adults 65 years and older. Both vaccines are given to persons with weakened immune systems or certain medical conditions or risk factors.
- Side effects of both vaccines are most commonly injection-site reactions.
- Duration of vaccine protection from Prevnar 13 is lifelong; no booster is required. Duration of protection from Pneumovax 23 is at least 5 years; 1 or 2 boosters are recommended for certain persons.
Pneumococcal disease, a bacterial infection occurring worldwide and transmitted person to person through direct contact with respiratory secretions from infected persons or carriers, is a leading cause of serious illness, especially among unvaccinated children and adults. Travelers are at risk of respiratory illness of all kinds but are generally not at increased risk for serious pneumococcal disease (e.g., invasive pneumococcal disease), except for persons with certain immunocompromising conditions and those who are very young or very old. Routine childhood vaccination in most developing countries has reduced circulation of some serotypes (variations) of bacteria in the community, but these types may still be circulating in countries with lower vaccination rates.
Pneumococcal disease occurs worldwide but is more common in developing countries, with most deaths occurring in Africa and Asia. In temperate climates, pneumococcal disease is more prevalent in winter and early spring.
Pneumococcal disease is mainly transmitted person to person via direct contact with respiratory droplets or secretions (e.g., mucus or saliva) from infected persons or from healthy carriers of the bacteria.
Risk is increased for infants, young children, and the elderly (especially in crowded settings) and for persons with viral upper respiratory infections, underlying medical conditions, and weakened immune systems.
On aircraft, risk for infection (although very low) exists for persons sitting within a 2-seat range (in back, front, and beside) of an infectious traveler.
Symptoms most commonly appear 1 to 3 days following exposure and include sudden onset of fever, chills, productive cough (with or without pus or blood-tinged sputum), and general discomfort. Chest pain, difficulty or rapid breathing, and shortness of breath may also occur. Fever, shortness of breath, or altered mental status may be the initial symptoms in the elderly.
Consequences of Infection
Pneumococcal disease can lead to meningitis (inflammation of the brain membranes causing stiff neck, headache, lack of energy, or seizures), respiratory failure, or blood infection.
Need for Medical Assistance
Persons who develop symptoms of pneumococcal disease should seek medical attention.
Observe good respiratory hygiene (cough and sneeze etiquette) and hand hygiene (frequent, thorough handwashing). Penicillin can also prevent pneumococcal infection in certain persons. Immune globulin (a human blood-derived product) may be given as temporary protection for children with certain medical conditions who have serious recurrent bacterial infections.
Two pneumococcal vaccines (Prevnar 13 and Pneumovax 23) are available in the U.S., and many people will need both. Routine childhood vaccination with Prevnar 13 in most developed countries over many years has reduced the rate of bacterial infection and serious pneumococcal disease in persons 65 years and older; however, Prevnar 13 vaccine serotypes may be still be circulating in countries with lower vaccination rates, thus increasing risk in this age group.
- Prevnar 13 is given routinely as a childhood vaccination to children aged 2-59 months and is recommended for all persons 5 years and older with certain medical conditions placing them at higher risk. Travelers 65 years and older visiting countries with lower vaccination rates may also receive this vaccine following discussion with the health care provider.
- Pneumovax 23 is given routinely to persons 65 years and older, persons 2 years and older with certain medical conditions placing them at higher risk, cigarette smokers, and residents of nursing homes or other long-term care facilities.
The most common vaccine side effects include injection-site reactions such as fever, pain, swelling, and redness. Fever, decreased appetite, irritability, and increased or decreased sleeping may also occur with Prevnar 13.
Persons with underlying medical conditions or those who have concerns about the vaccine should speak to their health care provider before vaccine administration.
Prevnar 13 is given as follows:
- Routine, regardless of travel, for children 15 months and younger: 4 doses, given at ages 2, 4, 6, and 12-15 months
- If earlier protection is needed for travel, the first 3 doses may be given as soon as 4 weeks apart. Different regimens apply if vaccination was started late.
- Children 18 years or younger with certain medical conditions: 1 or 2 doses
- Adults aged 19-64 years who are immunocompromised: 1 dose
- Unvaccinated adults 65 years and older with travel to risk country: 1 dose
- Many people will require both Prevnar 13 and Pneumovax 23; they cannot be administered within 8 weeks of each other. Prevnar 13 should be given first.
Booster doses of Prevnar 13 are not needed.
Pneumovax 23 is given as follows:
- Routine, regardless of travel, for all adults 65 years and older: 1 dose
- Delay until at least 5 years after the previous dose if 1 or more doses of Pneumovax 23 were given prior to age 65 years for an indicated condition.
- Persons 2 years and older who are immunocompromised or have certain medical conditions or risk factors: 1 dose
- A minimum interval of 8 weeks between a dose of Pneumovax 23 (if indicated) and a previously given dose of Prevnar 13 may be used.
A second dose of Pneumovax 23 is needed in some persons younger than 65 years; administration should be 5 years after the first Pneumovax 23 dose.